The obesity drug market is shifting from scarcity to fierce competition, as new pills, direct-to-consumer pricing and looming patent expirations upend what was once a two-player race. With one in five U.S. households now including a GLP-1 user, we will break down what the next phase means for healthcare investors and for the food, apparel and employer health costs these drugs are already reshaping.

Also in this podcast: EME - Emcor group Inc., MDT - Medtronic PLC, GLW - Corning Inc., CROX - Crocs Inc., LULU - Lululemon Athletica Inc., BAH - Booz Allen Hamilton Holding Corp; also, a question about XRP, plus Luke's MARKET WRAP UP, and his topic talking points: "Freight Costs" and “Household financial Health”.

Our Sponsors:
* Check out Anthropic and use my code claud.ai/invest for a great deal: https://www.anthropic.com
* Check out Quince and use my code quince.com/INVEST for a great deal: https://www.quince.com

Advertising Inquiries: https://redcircle.com/brands

The Weight-Loss Drug Boom Hits Its Middl...